Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Third Quarter 2025
Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.
Press Releases
October 22, 2025
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
October 20, 2025
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Upcoming Events
3Nov
2023
Berenberg Pharma CFO Call Series 2025
16:30 - 17:30 CET (Virtual)
Conferences
10Nov
2025
Guggenheim’s 2nd Annual Healthcare Innovation Conference
10:00 - 17:00 EST (Boston)
Conferences
12Nov
2025
Buy-side Healthcare CEO Summit
08:00 - 16:00 EST (Washington D.C.)
Conferences
30th Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00